Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications
William Sohn(Vanderbilt University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center), Mia Hashibe(University of California, Los Angeles), Tatsuki Koyama(Vanderbilt University Medical Center), Sherrie H. Kaplan(University of California, Irvine), Sheldon Greenfield(University of California, Irvine), Lisa E. Paddock(Rutgers, The State University of New Jersey), Sharon Phillips(Vanderbilt University Medical Center), Ann S. Hamilton(University of Southern California), Karen E. Hoffman(The University of Texas MD Anderson Cancer Center), Xiao‐Cheng Wu(Louisiana State University Health Sciences Center New Orleans), Antoinette M. Stroup(Rutgers, The State University of New Jersey), Matthew J. Resnick(Vanderbilt University Medical Center), Michael Goodman(Emory University)
Cited by 18
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25
|Nature|2008|1.3k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688